| Name | Title | Contact Details |
|---|
Tucson Medical Center, licensed at 607 beds, has been Tucson`s locally governed nonprofit regional hospital for 70 years. TMC is Southern Arizona`s leading provider for emergency care and pediatric care (including Tucson`s first Pediatric Emergency Department), with top-notch intensive care units for adults, children and newborns. Other specialty areas include women`s, maternity, cardiovascular, orthopaedic, neuroscience, hospice, imaging and senior services. TMC earned certification as a Primary Stroke Center, accreditation as a Chest Pain Center, and the Gold Plus Achievement Award for stroke programs from the American Heart Association/American Stroke Association. TMC is also a recipient of the AHA/ASA`s Target: Stroke Honor Roll. TMC HealthCare is Southern Arizona`s locally governed nonprofit system, the corporate entity that includes Tucson Medical Center and Saguaro Physicians.
Symbion Research International is a Agoura Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alfa Dental Management is a dental services organization that specializes in implementing highly effective management and business development strategies for dental practices. They partner with dental practices that are positioned for expansion and gro...
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.
Centric Medical Communications, Inc. is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.